Coronary artery disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PCSK9 14
• SGLT2 12
• APOE 0
• GLP-1 4
• NLRP3 2
• PPAR 0
• IL-6 2
• NRF2 0
• CD40 0
• AKT 0
• VEGF 0
• TNF 1
• PI3K 0
• SIRT1 0
• TLR4 0
• TP53 0
• HMGB1 0
• STAT3 0
• HIF-1 0
• AMPK 0
• IL-1 1
• JAK 0
• MMP-9 0
• STING 1
• ACE2 0
• ERK 0
• GIP 1
• mTOR 0
• PD-1 0
• BDNF 0
• COX-2 0
• CXCR4 1
• DPP-4 0
• FGFR 0
• HER2 0
• IL-17 1
• MAPK 0
• PTEN 0
• TREM2 0
• YAP 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APP 0
• BACE1 0
• BCL-2 0
• BRAF 0
• BTK 0
• CCR5 0
• CGRP 0
• CTLA-4 0
• CTNNB1 0
• EZH2 0
• FOXP3 0
• FTO 0
• G6PD 0
• GPX4 0
• HSP90 0
• IL-4 1
• LRRK2 0

12 of 12+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unmasking the Perivascular Adipose Tissue's Role in Diabetic Vascular Disease From Molecular Clues to Clinical Impact (IMAPERFAT)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €236,340· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Delineating and eradicating cardiovascular inflammageing (DEFLAME)

  Technische Universiteit Eindhoven· Eindhoven, Netherlands· EU contribution €2,500,000· until Feb 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Predicting Female-Predominant Cardiovascular Dissections via multi-scale Hormonal, Imaging, and Biomechanical Integration (DISSEX)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €1,499,585· until Feb 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DEVELOPMENT OF A NANOHYBRID SYSTEM BASED WEARABLE MICROFLUIDIC PHOTOELECTROCHEMICAL SENSOR FOR THE ON-DEMAND cTnI DETECTION (NANOPEC)

  Kauno Technologijos Universitetas· Kaunas, Lithuania· EU contribution €196,976· until Jan 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Socio-Environmental Determinants of Health in Small States (SEEDS)

  Universita Ta Malta· Msida, Malta· EU contribution €205,314· until Jan 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 72 running projects, newest first. Listed amounts together: €236.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI

  NCT05613426· Henan Institute of Cardiovascular Epidemiology· Updated 22 May 2026

  “Slow patient enrollment and lack of financial support”Registry text, quoted unchanged. Source

• Withdrawn

  Immunomodulatory Effects of PCSK9 Inhibition

  NCT05720156· Massachusetts General Hospital· Updated 26 Sept 2025

  “Lack of Feasibility”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Novartis Pharmaceuticals· Source

• Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

  NCT05360446· Novartis Pharmaceuticals· Source

• A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

  NCT07803679· Amgen· Source

• Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

  NCT05192941· Novartis Pharmaceuticals· Source

• Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

  NCT06863545· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)

  NCT06791031· West China Hospital· Source

• Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

  NCT07084259· Hanyang University Seoul Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 14
• Organoids 1
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 4
• Gene Expression Profiling 48
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 6
• Proteomics 68
• Metabolomics 41
• Mass Spectrometry 5
• Flow Cytometry 26
• Immunohistochemistry 12
• Positron-Emission Tomography 64
• Magnetic Resonance Imaging 66
• Machine Learning 161
• Deep Learning 85
• Cohort Studies 405
• Genome-Wide Association Study 163

• Integrative Single-Cell Transcriptomics, Multi-Omics Analyses, and Computational Pharmacology Reveal Macrophage Heterogeneity and the Putative THBS1-CD36 Axis in Coronary Atherosclerosis.

  Chem Biol Drug Des, Oct 2026

• MGST3 defines a mitochondrial-health-associated M2 macrophage state in atherosclerosis: integrative multi-omics, single-cell mediation, and functional validation.

  Front Immunol, Sept 2026

• Integrative Transcriptomic Analysis and Single-Cell Characterization Identify RTN4 as a Candidate PBMC-Derived Hub Gene Associated with COPD and Coronary Artery Disease.

  Genes (Basel), Aug 2026

• dioscRi enables transferable prediction of clinical outcomes in multi-parameter cytometry data.

  Nat Commun, Aug 2026

• Endocrine-disrupting chemical-induced gene networks confer coronary heart disease risk revealed by causal inference and single-cell analyses.

  Food Chem Toxicol, Aug 2026

• Single-cell transcriptomics uncovers endothelial progenitor-like remodelling driving human coronary atherosclerosis progression.

  Nat Cell Biol, Jul 2026

• Metabolic Heterogeneity Across Heart Failure Subtypes Defined by Integrative Multi-Omics Analysis.

  J Cardiovasc Transl Res, Jun 2026

• Immunothrombotic Cell-Cell Communication Networks in Coronary Atherosclerosis: Critical Insights from Single-Cell and Spatial Systems Biology.

  Int J Mol Sci, Jun 2026

• Single-Cell Studies Advance Understanding of the Genetic and Molecular Basis of Atherosclerosis.

  Circ Res, Jun 2026

• The exploration to identify key molecules in the interaction between endothelial cells and mono-macrophages in atherosclerosis based on the single cell transcriptome.

  BMC Cardiovasc Disord, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.